Advances in the study of nitric oxide-donating drugs

Yaoxue Xuebao

Volumn 44, Issue 11, 2009, Pages 1200-1210

  Zhang, Yi Hua ^a   Peng, Si Xun ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Effector; Messenger; Nitric oxide (NO); NO donating drugs

Indexed keywords

ACETYLSALICYLIC ACID; NITRIC OXIDE; TACRINE DERIVATIVE;

DRUG RESEARCH; DRUG STRUCTURE; FOOD AND DRUG ADMINISTRATION; HUMAN; IC 50; PRACTICE GUIDELINE; REVIEW;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; ASPIRIN; AZO COMPOUNDS; CARDIOVASCULAR DISEASES; CELL LINE, TUMOR; DRUG DESIGN; HUMANS; NEOPLASMS; NITRATES; NITRIC OXIDE; NITRIC OXIDE DONORS; PIPERAZINES; SIGNAL TRANSDUCTION;

EID: 76049116952     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Scatena R, Bottoni P, Martorana GE, et al. Nitric oxide donor drugs: an update on pathophysiology and therapeutic potential [J]. Expert Opin Investig Drugs, 2005, 14: 835-846.
2. Miller MR, Megson IL. Recent developments in nitric oxide donor drugs [J]. Br J Pharmacol, 2007, 151: 305-321.
3. Zhang YH, Tian JD, Peng SX. Targeting of nitric oxide-donor and related drugs [J]. Acta Pharm Sin 2006, 41: 481-486.
4. Liu J, Li C, Qu W, et al. Nitric oxide prodrugs and metallochemotherapeutics: JS-K and CB-3-100 enhance arsenic and cisplatin cytolethality by increasing cellular accumulation [J]. Mol Cancer Ther, 2004, 3: 709-714.
5. Saavedra JE, Srinivasan A, Buzard GS, et al. PABA/NO as an anticancer lead: analogue synthesis, structure revision, solution chemistry, reactivity toward glutathione, and in vitro activity [J]. J Med Chem, 2006, 49: 1157-1164.
6. Chakrapani H, Kalathur RC, Maciag AE, et al. Synthesis, mechanistic studies, and anti-proliferative activity of glutathione/ glutathione S-transferase-activated nitric oxide prodrugs [J]. Bioorg Med Chem, 2008, 16: 9764-9771.
7. Chakrapani H, Wilde TC, Citro ML, et al. Synthesis, nitric oxide release, and anti-leukemic activity of glutathione-activated nitric oxide prodrugs: structural analogues of PABA/ NO, an anti-cancer lead compound [J]. Bioorg Med Chem, 2008, 16: 2657-2664.
8. Chen C, Shi YQ, Song J, et al. A glycosylated nitric oxide donor, β-Gal-NONOate, and its site-specific antitumor activity [J]. Arch Pharm (Weinheim), 2006, 339: 366-371.
9. Tang XP, Xian M, Trikha M, et al. Synthesis of peptide-diazeniumdiolate conjugates: towards enzyme activated antitumor agents [J]. Tetrahedron Lett, 2001, 42: 2625-2629.
10. Yasuda H. Solid tumor physiology and hypoxia-induced chemo/radio- resistance: novel strategy for cancer therapy: nitric oxide donor as a therapeutic enhancer [J]. Nitric Oxide, 2008, 19: 205-216.
11. Yasuda H, Yamaya M, Nakayama K. Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small cell lung cancer [J]. J Clin Oncol, 2006, 24: 688-694.
12. Maksimovic-Ivanic D, Mijatovic S, Harhaji L, et al. Anticancer properties of the novel nitric oxide-donating compound (S, R)-3-phenyl-4, 5-dihydro-5-isoxazole acetic acid-nitric oxide in vitro and in vivo [J]. Mol Cancer Ther, 2008, 7: 510-520.
13. Cai TB, Tang XP, Nagorski J, et al. Synthesis and cytotoxicity of 5-fluorouracil/diazeniumdiolate conjugates [J]. Bioorg Med Chem, 2003, 11: 4971-4975.
14. Rigas B, Kashfi K. Nitric oxide-donating NSAIDs as agents for cancer prevention [J]. Trends Mol Med, 2004, 10: 324-330.
15. Rigas B. Novel agents for cancer prevention based on nitric oxide [J]. Biochem Soc Trans, 2007, 35: 136-138.
16. Stewart GD, Nanda J, Brown DJ, et al. NO-sulindac inhibits the hypoxia response of PC-3 prostate cancer cells via the Akt signaling pathway [J]. Int J Cancer, 2009, 124: 223-232.
17. Jeong DW, Kim YH, Kim HH, et al. Dose-linear pharmacokinetics of oleanolic acid after intravenous and oral administration in rats [J]. Biopharm Drug Dispos, 2007, 28: 51-57.
18. Ovesna Z, Vachalkova A, Horvathova K, et al. Pentacyclic triterpenoic acids: new chemoprotective compounds [J]. Neoplasma, 2004, 51: 327-333.
19. Cipak L, Grausova L, Miadokova E, et al. Dual activity of triterpenoids: apoptotic versus antidifferentiation effects [J]. Arch Toxicol, 2006, 80: 429-435.
20. Huang D, Ding Y, Li Y, et al. Anti-tumor activity of a 3-oxo derivative of oleanolic acid [J]. Cancer Lett, 2006, 233: 289-296.
21. Wu LM, Wu XX, Sun Y, et al. A novel synthetic oleanolic acid derivative (CPU-II(2)) attenuates liver fibrosis in mice through regulating the function of hepatic stellate cells [J]. J Biomed Sci, 2008, 15: 251-259.
22. Chen L, Zhang YH, Kong X, et al. Design, synthesis, and antihepatocellular carcinoma activity of nitric oxide releasing derivatives of oleanolic acid [J]. J Med Chem, 2008, 51: 4834-4838.
23. Wu XJ, Tang XP, Xian M, et al. Synthesis and cytotoxicities of mannose conjugated S-nitroso-N-acetylpenicillamine (SNAP) [J]. Bioorg Med Chem, 2002, 10: 2303-2307.
24. Huang Z. Studies on design, synthesis of site-targeting and NO-donating oleanolic acid derivatives as anti-hepatocellular carcinoma agents [D]. Nanjing: China Pharmaceutical University, 2009.
25. Shen LH, Lai YS, Zhang YH, et al. Synthesis and anti-tumor activities of nitrate derivatives of glycyrrhetinic acid [J]. J China Pharm Univ, 2008, 39: 103-107.
26. Kong XW, Zhang YH, Wang T, et al. Synthesis and cytotoxic evaluation of novel dimethyl [1,1′-biphenyl]-2,2′-dicarboxylates bearing 1,3,4-thiadiazole moieties [J]. Chem Biodivers, 2008, 5: 1743-1752.
27. Wang T, Zhang YH, Kong XW, et al. Synthesis and biological evaluation of nitric oxide-donating thalidomide analogues as anticancer agents [J]. Chem Biodivers, 2009, 6: 466-474.
28. He BC, Zhang YH, Lai YS, et al. Studies on synthesis and anti-tumor activity of conjugates of furoxans to N-(4-hydroxyphenyl) retinamide [J]. Chin J Org Chem, 2007, 27: 629-635.
29. Wallace JL, Ignarro LJ, Fiorucci S. Potential cardioprotective actions of no-releasing aspirin [J]. Nat Rev Drug Discov, 2002, 1: 375-382.
30. Shukla N, Angelini GD, Ascione R. Nitric oxide donating aspirins: novel drugs for the treatment of saphenous vein graft failure [J]. Ann Thorac Surg, 2003, 75: 1437-1442.
31. Lazzarato L, Donnola M, Rolando B, et al. Searching for new NO-donor aspirin-like molecules: a new class of nitrooxy-acyl derivatives of salicylic acid [J]. J Med Chem, 2008, 51: 1894-1903.
32. Zhou Z, Jiang LY, Zhang YH, et al. Synthesis and antithrombotic activity of acetylsalicyl p-coumaric acid coupled with furoxans and nitrates [J]. Chin J Org Chem 2006, 26: 1403-1408.
33. Zhou Z, Jiang LY, Zhang YH, et al. Synthesis and antithrombotic activity of acetylsalicyl ferulic acid-coupling furoxans and nitrates [J]. Acta Pharm Sin, 2006, 41: 1050-1056.
34. Zhou Z, Lai YS, Zhang YH, et al. Synthesis and antithrombotic activity of 3-aryl-1,2,3,4-oxatriazole-5-imine-aoupled aspirin [J]. Chin J Org Chem, 2008, 286: 819-824.
35. Zhang Y, Wang L, Zhang L, et al. Effects of 2-(1-hydroxypentyl)-benzoate on platelet aggregation and thrombus formation in rats [J]. Drug Dev Res, 2004, 63: 174-180.
36. Min ZL, Zhang YH, Zhuang P, et al. Synthesis and anti-platelet activities of nitric oxide-releasing derivatives of 3-butylphthalide [J]. J China Pharm Univ, 2008, 39: 392-397.
37. Fruttero R, Boschi D, Di Stilo A, et al. The furoxan system as a useful tool for balancing "hybrids" with mixed alpha 1-antagonist and NO-like vasodilator activities [J]. J Med Chem, 1995, 38: 4944-4949.
38. Decker M, König A, Glusa E, et al. Synthesis and vasorelaxant properties of hybrid molecules out of NO-donors and the beta-receptor blocking drug propranolol [J]. Bioorg Med Chem Lett, 2004, 14: 4995-4997.
39. de Nigris F, Mancini FP, Balestrieri ML, et al. Therapeutic dose of nebivolol, a nitric oxide-releasing b-blocker, reduces atherosclerosis in cholesterol-fed rabbits [J]. Nitric Oxide, 2008, 19: 57-63.
40. Di Stilo A, Visentin S, Cena C, et al. New 1,4-dihydropyridines conjugated to furoxanyl moieties, endowed with both nitric oxide-like and calcium channel antagonist vasodilator activities [J]. J Med Chem, 1998, 41: 5393-5401.
41. Harada N, Miura T, Dairaku Y, et al. NO donor-activated PKC-delta plays a pivotal role in ischemic myocardial protection through accelerated opening of mitochondrial K-ATP channels [J]. J Cardiovasc Pharmacol, 2004, 44: 35-41.
42. Xu X, Zhang YH, Peng SX, et al. Study on NO-donating antihypertensive agents I. Synthesis and antihypertensive activity of C-3 nitrate or furoxan substituted benzopyrans [J]. J China Pharm Univ, 2005, 36: 488-495.
43. Tsui DY, Gambino A, Wanstall JC. S-nitrosocaptopril: in vitro characterization of pulmonary vascular effects in rats [J]. Br J Pharmacol, 2003, 138: 855-864.
44. Iwanaga Y, Gu Y, Dieterle T, et al. A nitric oxide-releasing derivative of enalapril, NCX 899, prevents progressive cardiac dysfunction and remodeling in hamsters with heart failure [J]. FASEB J, 2004, 18: 587-588.
45. Breschi MC, Calderone V, Digiacomo M, et al. NO sartans: a new class of pharmacodynamic hybrids as cardiovascular drugs [J]. J Med Chem, 2004, 47: 5597-5600.
46. Breschi MC, Calderone V, Digiacomo M, et al. New NO-releasing pharmacodynamic hybrids of losartan and its active metabolite: design, synthesis, and biopharmacological properties [J]. J Med Chem, 2006, 49: 2628-2639.
47. Li YQ, Ji H, Zhang YH, et al. WB1106, a novel nitric oxide-releasing derivative of telmisartan, inhibits hypertension and improves glucose metabolism in rats [J]. Eur J Pharmacol, 2007, 577: 100-108.
48. 2-acetoxymethyl-protected diazeniumdiolate-based NSAIDs (NONO-NSAIDs): synthesis, nitric oxide release, and biological evaluation studies [J]. Bioorg Med Chem, 2007, 15: 4767-4774.
49. Abdellatif KR, Chowdhury MA, Dong Y, et al. Diazen-1-ium-1,2-diolated and nitrooxyethyl nitric oxide donor ester prodrugs of anti-inflammatory (E)-2-(aryl)-3-(4-methanesulfonylphenyl) acrylic acids: synthesis, cyclooxygenase inhibition, and nitric oxide release studies [J]. Bioorg Med Chem, 2008, 16: 3302-3308.
50. Abdellatif KR, Chowdhury MA, Dong Y, et al. Dinitroglyceryl and diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of aspirin, indomethacin and ibuprofen: synthesis, biological evaluation and nitric oxide release studies [J]. Bioorg Med Chem Lett, 2009, 19: 3014- 3018.
51. Botta M, Distrutti E, Mencarelli A, et al. Anti-inflammatory activity of a new class of nitric oxide synthase inhibitors that release nitric oxide [J]. ChemMedChem, 2008, 3: 1580-1588.
52. Li RW, Zhang YH, Ji H, et al. Synthesis and anti-inflammatory activity of benzenesulfonylfuroxan-coupled diclofenac [J]. Acta Pharm Sin, 2001, 36: 821-826.
53. Li R, Zhang YH, Ji H, et al. Synthesis and anti-inflammatory analgesic activities of phenylfuroxan-coupled diclofenac [J]. Acta Pharm Sin, 2002, 37: 27-32.
54. Feng XC, Ji H, Zhang YH, et al. Effect of ZLR-8 on the healing of gastric ulcer and NO releasing in vitro [J]. J China Pharm Univ, 2004, 35: 357-360.
55. Wang WD, Zhang YH, Zhang ZG, et al. Synthesis and anti-inflammatory analgesic activities of 2-(2,6-dichlorophenyl-amino)-benzeneacetic acid (3-nitroxymethyl) phenyl ester [J]. J China Pharm Univ, 2003, 34: 13-16.
56. Thatcher GRJ, Bennett BM, Reynolds JN. Nitric oxide mimetic molecules as therapeutic agents in Alzheimer's disease [J]. Curr Alzheimer Res, 2005, 2: 171-182.
57. Bennet BM, Reynolds JN, Prusky GT, et al. Cognitive deficits in rats after forebrain cholinergic depletion are reversed by a novel NO mimetic nitrate ester [J]. Neuropsychopharmacology, 2007, 32: 505-513.
58. Green A, Bender R. Therapies for cognition and learning enhancement: CA 2649760 [P]. 2009-7-14.
59. Munoz B, Prasit P, Reger TS. Nitric oxide releasing drugs for Alzheimer's disease: US 20050054714 [P]. 2005-3-10.
60. Fang L, Appenroth D, Decker M, et al. Synthesis and biological evaluation of NO-donor-tacrine hybrids as hepatoprotective anti-alzheimer drug candidates [J]. J Med Chem, 2008, 51: 713-716.
61. Fang L, Appenroth D, Decker M, et al. NO-donating tacrine hybrid compounds improve scopolamine-induced cognition impairment and show less hepatotoxicity [J]. J Med Chem, 2008, 51: 7666-7669.
62. Harada K, Supriatno, Kawaguchi S, et al. Overexpression of iNOS gene suppresses the tumorigenicity and metastasis of oral cancer cells [J]. In Vivo, 2004, 18: 449-455.
63. Wang Z, Cook T, Alber S, et al. Adenoviral gene transfer of the human inducible nitric oxide synthase gene enhances the radiation response of human colorectal cancer associated with alterations in tumor vascularity [J]. Cancer Res, 2004, 64: 1386-1395.
64. Xu W, Liu L, Charles IG. Microencapsulated iNOS-expressing cells cause tumor suppression in mice [J]. FASEB J, 2002, 16: 213-215.
65. Mazzone M, Carmeliet P. A lifeline for suffocating tissues [J]. Nature, 2008, 453: 1194-1195.
66. Kumar D, Branch BG, Pattillo CB, et al. Chronic sodium nitrite therapy augments ischemia-induced angiogenesis and arteriogenesis [J]. Proc Natl Acad Sci USA, 2008, 105: 7540-7545.
67. Xuan B, Xu XR, Chiou GC, et al. Relationship between nitric oxide production and choroidal blood flow [J]. J Ocular Pharmacol Ther, 2003, 19: 247-253.
68. Ji XB, Zhang YH, Lai YS, et al. Synthesis and biological evaluation of enantiomers of ZX-5 as novel anti-AMD agents [C]. Berlin: 50th Anniversary Meeting. Eighth Tetrahedron Symposium: Delegate Manual. 2007: 92-93.
69. Guo Z. Strategy of molecular drug design: dual-target drug design [J]. Acta Pharm Sin, 2009, 44: 209-218.
70. Xu Y, Li X. Multi-target therapeutics and new drug discovery [J]. Acta Pharm Sin, 2009, 44: 226-230..